Compare SWMR & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWMR | ANL |
|---|---|---|
| Founded | 2023 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.9M | 703.3M |
| IPO Year | 2026 | 2022 |
| Metric | SWMR | ANL |
|---|---|---|
| Price | $33.20 | $14.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 975.8K | 677.7K |
| Earning Date | 05-20-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,862.05 | $36.02 |
| Revenue Next Year | $177.93 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.75 | $0.88 |
| 52 Week High | $68.97 | $17.25 |
| Indicator | SWMR | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 47.18 | 60.71 |
| Support Level | N/A | $1.36 |
| Resistance Level | $68.97 | $17.25 |
| Average True Range (ATR) | 3.41 | 1.95 |
| MACD | -1.24 | -0.14 |
| Stochastic Oscillator | 0.00 | 67.68 |
Swarmer Inc is a provider of autonomous drone swarm software and AI solutions, specializing in vendor-agnostic technologies. It develops software platforms and artificial intelligence systems for defence applications, enabling military organisations to deploy and coordinate large-scale unmanned and autonomous systems. Its offerings include swarm coordination software, multi-domain unmanned systems integration, collaborative autonomy solutions, and command-and-control software for distributed robotic operations. Its key software and AI systems include: i) STYX AI Command & Control System, ii) MINAS Autonomy and Collaboration AI and iii) TRIDENT Embedded Drone Operating System. The company generates revenue through software license sales.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.